Patents by Inventor Zhaogen Chen

Zhaogen Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AT2R ANTAGONISTS AND USES THEREOF
    Publication number: 20250074875
    Abstract: This invention provides certain piperidine compounds as AT2R antagonists. e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof, and methods of using the same to treat pain associated with AT2R activity.
    Type: Application
    Filed: September 6, 2024
    Publication date: March 6, 2025
    Inventors: Thomas James BEAUCHAMP, Zhaogen CHEN, Scott Eugene CONNER, Jon Andre ERICKSON, Maria Cristina GARCIA PAREDES, Jayana Pankajkumar LINESWALA, Emanuele SHER, Bishnu THAPA, Leonard Larry WINNEROSKI, II
  • ATR antagonists and uses thereof
    Patent number: 12122750
    Abstract: This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof, and methods of using the same to treat pain associated with AT2R activity.
    Type: Grant
    Filed: May 11, 2023
    Date of Patent: October 22, 2024
    Assignee: Eli Lilly and Company
    Inventors: Thomas James Beauchamp, Zhaogen Chen, Scott Eugene Conner, Jon Andre Erickson, Maria Cristina Garcia Paredes, Jayana Pankajkumar Lineswala, Emanuele Sher, Bishnu Thapa, Leonard Larry Winneroski
  • 7 (methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
    Patent number: 12060356
    Abstract: The present invention provides a compound of Formula (I) wherein R is (II) or (III); or a pharmaceutically acceptable salt thereof, useful for treating psoriasis or systemic lupus erythematosus.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 13, 2024
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Theodore Curtis Jessop
  • Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
    Patent number: 11891400
    Abstract: The present invention provides a compound of Formula I: wherein R is methyl or ethyl; or a pharmaceutically acceptable salt thereof useful for treating psoriasis or systemic lupus erythematosus.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: February 6, 2024
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Jon Andre Erickson, Gaiying Zhao
  • AT2R ANTAGONISTS AND USES THEREOF
    Publication number: 20230373919
    Abstract: This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof, and methods of using the same to treat pain associated with AT2R activity.
    Type: Application
    Filed: May 11, 2023
    Publication date: November 23, 2023
    Inventors: Thomas James BEAUCHAMP, Zhaogen CHEN, Scott Eugene CONNER, Jon Andre ERICKSON, Maria Cristina GARCIA PAREDES, Jayana Pankajkumar LINESWALA, Emanuele SHER, Bishnu THAPA, Leonard Larry WINNEROSKI, II
  • Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of interferon signaling
    Patent number: 11634423
    Abstract: The present invention provides a compound of Formula I: wherein R is or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: April 25, 2023
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Zhaogen Chen, Theodore Curtis Jessop
  • 7 (METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES
    Publication number: 20220024933
    Abstract: The present invention provides a compound of Formula (I) wherein R is (II) or (III); or a pharmaceutically acceptable salt thereof, useful for treating psoriasis or systemic lupus erythematosus.
    Type: Application
    Filed: December 4, 2019
    Publication date: January 27, 2022
    Inventors: Zhaogen CHEN, Theodore Curtis JESSOP
  • 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS
    Publication number: 20210253581
    Abstract: The present invention provides a compound of Formula I: wherein R is or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 19, 2021
    Inventors: Thomas John BLEISCH, Zhaogen CHEN, Theodore Curtis JESSOP
  • PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20210188861
    Abstract: The present invention provides a compound of Formula I: wherein R is methyl or ethyl; or a pharmaceutically acceptable salt thereof useful for treating psoriasis or systemic lupus erythematosus.
    Type: Application
    Filed: September 4, 2019
    Publication date: June 24, 2021
    Inventors: Zhaogen CHEN, Jon Andre ERICKSON, Gaiying ZHAO
  • Thiophene pyrazolopyrimidine compounds
    Patent number: 8110580
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: February 7, 2012
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Shaojuan Jia, James Lee Toth
  • Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 8088776
    Abstract: The present invention discloses novel compounds of Formula I: possessing 11 ?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ?-HSD type 1 activity.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: January 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Ronald Jay Hinklin, Gary Alan Hite, Alexei Pavlovych Krasutsky, Renhua Li, Jefferson Ray McCowan, Ashraf Saeed, Nancy June Snyder, James Lee Toth, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
  • N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
    Patent number: 8044090
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: October 25, 2011
    Assignee: Eli Lilly
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • Thiazole pyrazolopyrimidines CRF1 receptor antagonists
    Patent number: 8030304
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: October 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Jason Kenneth Myers, Takako Takakuwa, James Lee Toth
  • Thiazole pyrazolopyrimidines CRF1 receptor antagonists
    Publication number: 20100222339
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Application
    Filed: September 17, 2007
    Publication date: September 2, 2010
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Jason Kenneth Myers, Takako Takakuwa, James Lee Toth
  • CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
    Publication number: 20100184764
    Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.
    Type: Application
    Filed: March 19, 2010
    Publication date: July 22, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Daniel AICHER, Mark Joseph CHICARELLI, Ronald Jay HINKLIN, Hongqi TIAN, Owen Brendan WALLACE, John Gordon ALLEN, Zhaogen CHEN, Thomas Edward MABRY, Jefferson Ray MCCOWAN, Nancy June SNYDER, Leonard Larry WINNEROSKI, JR.
  • Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 7713979
    Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: May 11, 2010
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Mark Joseph Chicarelli, Ronald Jay Hinklin, Hongqi Tian, Owen Brendan Wallace, John Gordon Allen, Zhaogen Chen, Thomas Edward Mabry, Jefferson Ray McCowan, Nancy June Snyder, Leonard Larry Winneroski, Jr.
  • THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20100022560
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Application
    Filed: September 13, 2007
    Publication date: January 28, 2010
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Shaojuan Jia, James Lee Toth
  • N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR
    Publication number: 20090306110
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Application
    Filed: July 16, 2009
    Publication date: December 10, 2009
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
    Publication number: 20090156571
    Abstract: The present invention discloses novel compounds of Formula I: possessing 11 ?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ?-HSD type 1 activity.
    Type: Application
    Filed: April 19, 2007
    Publication date: June 18, 2009
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Ronald Jay Hinklin, Gary Alan Hite, Alexei Pavlovych Krasutsky, Renhua Li, Jefferson Ray McCowan, Ashraf Saeed, Nancy June Snyder, James Lee Toth, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
  • Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1
    Publication number: 20080275043
    Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Fomula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.
    Type: Application
    Filed: October 26, 2005
    Publication date: November 6, 2008
    Inventors: Thomas Daniel Aicher, Mark Joseph Chicarelli, Ronald Jay Hinklin, Hongqi Tian, Owen Brendan Wallace, John Gordon Allen, Zhaogen Chen, Thomas Edward Mabry, Jefferson Ray McCowan, Nancy June Snyder, Leonard Larry Winneroski